Qiagen (NYSE:QGEN) PT Raised to $54.00 at JPMorgan Chase & Co.

Qiagen (NYSE:QGEN) had its price target lifted by research analysts at JPMorgan Chase & Co. from $52.00 to $54.00 in a research note issued on Tuesday, Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 23.43% from the stock’s current price.

Separately, Stifel Nicolaus lowered their target price on Qiagen from $55.00 to $45.00 and set a “hold” rating for the company in a research note on Wednesday, May 1st. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $51.17.

Qiagen Trading Up 0.0 %

NYSE QGEN opened at $43.75 on Tuesday. Qiagen has a fifty-two week low of $34.74 and a fifty-two week high of $47.70. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.45 and a current ratio of 1.84. The stock has a 50 day simple moving average of $43.01 and a two-hundred day simple moving average of $43.65. The stock has a market cap of $9.98 billion, a P/E ratio of 29.34, a price-to-earnings-growth ratio of 3.61 and a beta of 0.42.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Monday, April 29th. The company reported $0.46 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.02. Qiagen had a return on equity of 12.59% and a net margin of 17.38%. The business had revenue of $459.00 million during the quarter, compared to analysts’ expectations of $453.91 million. During the same quarter last year, the business posted $0.53 EPS. The business’s revenue was down 5.4% on a year-over-year basis. On average, analysts forecast that Qiagen will post 2.14 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Earnest Partners LLC raised its stake in Qiagen by 85.1% during the first quarter. Earnest Partners LLC now owns 3,427,605 shares of the company’s stock valued at $147,353,000 after buying an additional 1,576,259 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Qiagen by 13.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 91,763 shares of the company’s stock valued at $3,945,000 after buying an additional 10,683 shares during the last quarter. PEAK6 Investments LLC raised its stake in Qiagen by 270.0% during the first quarter. PEAK6 Investments LLC now owns 7,925 shares of the company’s stock valued at $341,000 after buying an additional 12,587 shares during the last quarter. Covestor Ltd raised its stake in Qiagen by 1,012.0% during the first quarter. Covestor Ltd now owns 5,015 shares of the company’s stock valued at $216,000 after buying an additional 4,564 shares during the last quarter. Finally, Edgestream Partners L.P. purchased a new position in Qiagen during the first quarter valued at $1,492,000. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.